Neuro-Oncología

1. Dra. Daysi Chi Ramírez
INOR

2.  Los resultados muy esperados de 3 grandes
estudios de Fase III en primera línea
terapéutica de pacientes portadores de
glioblastoma multiforme(GBM) fueron
presentados durante una sesión plenaria
realizada el domingo de 2 junio

3. Presented By Terri S. Armstrong, PhD, ANP-BC, FAANP at 2013 ASCO Annual Meeting

4. Presented By Terri S. Armstrong, PhD, ANP-BC, FAANP at 2013 ASCO Annual Meeting

5. Presented By Terri S. Armstrong, PhD, ANP-BC, FAANP at 2013 ASCO Annual Meeting

6. • Comparó el aporte del bevacizumab en primera
línea en asociación al tratamiento de referencia
versus el tratamiento estándar + placebo.
• Los resultados evidenciaron una diferencia
significativa de supervivencia libre de progresión
(PFS) en favor del brazo del bevacizumab pero sin
impacto sobre la supervivencia global (OS).
• Sin embargo, debido a su metodología inicial, este
ensayo fue considerado como NEGATIVO.

7. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

8. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

9. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

10. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

11. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

12. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

13. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

14. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

15. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

16. Presented By Wolfgang Wick, MD at 2013 ASCO Annual Meeting

17. • Evaluó también el efecto del bevacizumab en
primera línea terapéutica (#2002, W. Wick y
#2005, R. Henriksson).
• Los resultados definitivos serán presentados
durante el congreso de la ESMO, pero los
resultados preliminares en cuanto a PFS y OS
encuentran igualmente una mejoría
significativa del PFS (p<0.001) sin impacto
en la OS.
• Este ensayo fue considerado
metodológicamente POSITIVO (double end-
point).

18. • Fase III que evaluó en primera línea
terapéutica el beneficio del cilengitide
(#LBA 2009, R. Stupp), un inhibidor de las
integrinas αvβ3 et αvβ5, en complemento
al tratamiento estándar versus este
tratamiento solo.
• A pesar del excelente perfil de tolerancia,
no se evidenció ninguna ventaja en
términos de PFS ni de OS.

19. Presented By Jaishri O'Neill Blakeley, MD at 2013 ASCO Annual Meeting

20. GILARIUS
BELOB

21. Presented By Ulrich Herrlinger at 2013 ASCO Annual Meeting

22. Presented By Ulrich Herrlinger at 2013 ASCO Annual Meeting

23. Presented By Ulrich Herrlinger at 2013 ASCO Annual Meeting

24. Presented By Ulrich Herrlinger at 2013 ASCO Annual Meeting

25. Presented By Ulrich Herrlinger at 2013 ASCO Annual Meeting

26. Presented By Walter Taal at 2013 ASCO Annual Meeting

27. Presented By Walter Taal at 2013 ASCO Annual Meeting

28. RTOG 0825
AVAglio

29. RTOG 0825 AVAglio
tendencia a la
disminución de la
QoL de los pacientes
analizados en el
brazo del
bevacizumab a las
34 semanas del
tratamiento (#2003,
T. Armstrong)
no se empeoró y se
conservó
significativamente más
tiempo en el brazo
experimental (#2005, R
Henriksson), al igual que
autonomía de los
pacientes que se
evaluaron según la
duración de la
preservación del KPS ≥
70.

30. Presented By Roger Henriksson, MD, PhD at 2013 ASCO Annual Meeting

31. Presented By Robin Grant, MBChB, MD at 2013 ASCO Annual Meeting

32. Presented By Robin Grant, MBChB, MD at 2013 ASCO Annual Meeting

33. Presented By Robin Grant, MBChB, MD at 2013 ASCO Annual Meeting

34. Presented By Robin Grant, MBChB, MD at 2013 ASCO Annual Meeting

35. • Donepezil para prevenir los trastornos
cognitivos post RT cerebral (n°2006):
NEGATIVO

37. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

38. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

39. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

40. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

41. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

42. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

43. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

44. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

45. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

46. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

47. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

48. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

49. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

50. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

51. Presented By Brigitta G Baumert, MD, PhD, MBA at 2013 ASCO Annual Meeting

52. Presented By Barbara Jean Fisher, MD at 2013 ASCO Annual Meeting

53. Presented By Barbara Jean Fisher, MD at 2013 ASCO Annual Meeting

54. • En gliomas de bajo grado que requieren
tratamiento adyuvante post operatorio:
Aleatorización de RT versus temozolomide
(TMZ) en 1era línea (n°2007).
• Hasta la fecha: No hay diferencia en favor de
TMZ. Estos resultados serán actualizados en
los próximos años.

55. Linfoma PCNSL
Metástasis

70. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

71. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

72. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

73. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

74. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

75. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

76. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

77. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting

78. Presented By Kim Allyson Margolin, MD at 2013 ASCO Annual Meeting